- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Low Breast Density, Poor Breast Cancer Prognosis
Patients with breast cancer and very low mammographic breast density have a poorer prognosis.
Very low mammographic breast density is associated with higher tumor grade and predicted worse survival, according to a study published in the journal European Radiology.
Researchers from Finland examined the prognostic value of mammographic breast density (MBD) and any relationship with established prognostic factors in patients with invasive breast cancer.
The study included 270 women with breast cancer. The researchers classified MBD according to percentile density: <5%, 5%–10%, 10%–25%, 25%–50%, 50%–75%, and >75%. The cases were also categorized into very low density (VLD; <10%), low density (LOD; <25%) and mixed density (MID; >25%).
The researchers found that MBD was inversely associated with tumor grade. Patients with LOD breasts had worse prognoses compared to those with MID breasts.
The strongest significance was seen among patients with VLD breasts compared to the remaining patients. No other mammographic feature was prognostically significant.
"It is difficult to detect small tumors when screening dense breasts, and this results in a higher occurrence of clinically detectable interval cancers,” Professor Ritva Vanninen, said in a release. “In the U.S., it is nowadays mandatory to let patients know if they have dense breast tissue. This allows them to choose whether they wish to have further tests, for example a screening ultrasound."
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
